| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6200158 | Ophthalmology | 2016 | 9 Pages |
Abstract
At 2 years, bevacizumab and ranibizumab had an equivalent effect on visual acuity and reduction of central retinal thickness when administered according to a treat-and-extend protocol for nAMD. There was no significant difference in the number of serious adverse events between the treatment groups.
Keywords
CrtETDRSBCVACATTnAMDfluorescein angiographyOctbest-corrected visual acuityOptical coherence tomographyearly treatment diabetic retinopathy studyneovascular age-related macular degenerationcentral retinal thicknessconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)LUCASComparison of Age-Related Macular Degeneration Treatments Trials
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Karina MD, Emina MD, Inger MD, Vegard MD, Lars Haakon MD, Bettina MD, PhD, Hans MD, Kristian MD, Slavica MD, Terje R. MD, PhD, Leiv MD, PhD, Ragnheiður MD, PhD,